Although he was trained in mathematics and physics, Phil R. McKee has founded and built several successful companies, including TurboChef Technologies, Inc., which he led through the IPO process as president and CEO. He later founded Appliance Scientific and subsequently founded Appliance Innovation, Inc., serving both companies as chairman and CEO through their successful liquidity events. Mr. McKee’s inventions in heat transfer are used in more than 100,000 foodservice locations around the world. He holds more than 30 patents. In addition to product innovation, Mr. McKee has spent more than 25 years in all aspects of growing companies and as such serves as an advisor in capital formation, high capacity team building, product commercialization, product marketing, and domestic and international sales.
Following eradication of his own blood cancer, Mr. McKee became a benefactor of MD Anderson with an interest in natural killer (NK) cell therapy. This led to his investment in CytoSen Therapeutics, where he now leads the corporate development strategy with a zeal to bringing the benefits of both NK cell therapeutics and particle-based delivery systems to the global market and within a viable cost structure.
Dr. Carrier has extensive expertise in multiple biotherapeutic platforms and more than 20 years of scientific, business, and executive management experience in the biotechnology industry. He has led multiple corporate development initiatives throughout his career, most recently including Takeda board level financings for commercial manufacturing and capital expansion. Additionally, Dr. Carrier has managed over 25 corporate-level technology acquisitions, including both asset purchases and licensing agreements. He developed and taught courses on biotechnology valuations at the Smith School at the University of Maryland and most recently served as an Entrepreneur-in-Residence for the NC State Office of Technology Commercialization and New Ventures.
Prior to Takeda, Dr. Carrier served on multiple franchise-level committees at Merck, led the Cellular Medicine portfolio at Life Technologies, and was responsible for business strategy at Biologics Consulting Group. Throughout his career, Dr. Carrier has built successful teams and has established a strong global network in product development. Dr. Carrier received his Ph.D. in chemical engineering from the University of California, Berkeley and his MBA from the Darden School of Business at the University of Virginia.
Dr. Igarashi has a diverse background in life sciences and has played an instrumental role in executing the combination of Dr. Lee’s method of growing NK cells with Dr. Copik’s particle based natural killer (NK) cell stimulating technology. He has applied his biochemical and physico-chemical expertise to combine with immunology for developing and refining the nanoparticle based method for NK cell stimulation that could be used for ex vivo expansion as well as in vivo stimulation of therapeutic NK cells. Dr. Igarashi has been crucial in understanding the biochemical aspects of the plasma membrane particles interacting with NK cells and how they can be further innovated to add novel therapeutic dimensions for adoptive NK cell therapy.
Prior to joining CytoSen, Dr. Igarashi served on the faculty at the University of Central Florida as an assistant professor in the Department of Chemistry with a joint appointment in the Burnett School of Biomedical Sciences. Dr. Igarashi achieved his B.S. and M.S. in biochemistry at California State University Fullerton and Ph.D. in biochemistry at Utah State University and was a postdoctoral scholar at University of California, Berkeley.
Joseph S. Shan is Head of Clinical and Regulatory Affairs at CytoSen Therapeutics, where he is leading clinical development and regulatory submissions. Previously, Mr. Shan served as Vice President, Clinical and Regulatory Affairs at Peregrine Pharmaceuticals, where he was responsible for the design and execution of clinical trials and overseeing regulatory submissions. At Peregrine, he was instrumental in advancing the clinical development from pre-IND through Phase 3 clinical trials of the Company’s immuno-oncology candidates. Prior to Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter CardioVascular Group) and Sulzer Medica. Mr. Shan received his B.S. degree in physiological sciences from the University of California, Los Angeles and his MPH degree from the George Washington University in Washington, D.C. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals, and the Regulatory Affairs Professionals Society.
Dennis J. Jameson brings more than forty years of experience in building successful businesses while serving in C-level financial and management roles in both public and private companies. For CytoSen, Mr. Jameson is advising on administrative, audit and regulatory compliance. He currently serves as Chief Operating Officer (COO) for Appliance Innovation, Inc. Prior to this role, he served as president of a private company, where he led substantial revenue growth and eventually managed the sale of the company. Mr. Jameson has also held the position of Chief Financial Officer for NASDAQ-listed TurboChef Technologies, Inc. Mr. Jameson holds a B.S. degree in accounting from the University of Kentucky.